A healthy 29-year-old male received the first dose of the ChAdOx1-nCoV-19 vaccine (AstraZeneca). Four-days post-inoculation, he noted intermittent paraesthesia in extremities, which gradually became persistent. He was completely asymptomatic prior to the inoculation, with no fever, cough, shortness of breath, or gastrointestinal symptoms, including since receiving the vaccine. There was no family history of autonomic neuropathy. Clinical examination, including neurologic exam, was normal. Blood count, electrolytes, inflammatory markers, thyroid function, and folate were normal. Polymerase chain reaction assay for COVID-19 was negative. B12 was mildly low [161 ng/L (200–1000)] with a negative intrinsic factor antibody. He was started on B12 injections and Amitriptyline for neuralgia. His symptoms, nevertheless, persisted. Two months post-inoculation, he noted increased heart rate on smartwatch (Apple Inc., Figure 1A), with a significant change when standing (80–120 b.p.m.) vs. lying (50–60 b.p.m.). He then developed intermittent skin colour changes (dark-blue/white/dark-red) in acral areas (hands/feet/penis), with mottling and blood pooling/dependent acrocyanosis with sluggish capillary refill ( Figure 1B and C). He had intermittent palpitations, dizziness, and worsening of paraesthesia and skin colour changes especially with prolonged standing, exertion, food intake, or changes in the temperature in the environment, with no pre-syncope or syncope. He also developed difficulty achieving and maintaining an erection.